JAK inhibitor

This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...

Older adults with IBD are under-represented in trials, so age-specific benefits and harms of newer oral drugs (JAK inhibitors and S1P modulators) are uncertain. Clinicians and patients may need to weigh efficacy against...

Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.

For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...

This real-world multicenter study provides short-term effectiveness and safety data for upadacitinib in a difficult-to-treat Crohn’s population in China, which may inform treatment decisions and risk discussions.

Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.

This FDA drug-label update describes approved uses and safety warnings for tofacitinib, a JAK inhibitor used in immune-mediated diseases including ulcerative colitis. The boxed warnings highlight serious infection and...

If you or your clinician are using upadacitinib for Crohn’s, intestinal ultrasound early in treatment may help predict who will not respond and who is more likely to relapse on maintenance dosing, potentially guiding...

For people with UC on long-term tofacitinib, this trial provides evidence about the chances of keeping remission after stepping down dose and about safety differences between 10 mg and 5 mg twice daily over 30 months.

The review aggregates published instances where combining two advanced immunomodulators was followed by improvement in pyoderma gangrenosum, a serious skin complication often seen in people with IBD. However, the...

This case shows that upadacitinib, a JAK inhibitor used for refractory IBD, can cause severe anemia in rare cases but that dose reduction (rather than permanent discontinuation) may reversibly restore blood counts while...

A JAK inhibitor (upadacitinib) used for moderate–severe ulcerative colitis can cause neutropenia; this case report discusses how it was identified and managed, which matters for patients on the drug and clinicians...

Cure8 found this source from Journal of paediatrics and child health, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Upadacitinib. Open the original...

An expanded access program can allow people with Crohn's disease or ulcerative colitis to access upadacitinib before local approval when no other suitable treatments exist.

People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...

This analysis suggests upadacitinib works and has a similar safety and pharmacokinetic profile in East Asian patients with moderately to severely active ulcerative colitis as in the global trials, which may reassure...

Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...

Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...

This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...

This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...

The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...

People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.

The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...

For people hospitalized with acute severe ulcerative colitis, starting a JAK inhibitor together with IV steroids right away (rather than waiting for steroids to fail) could potentially control inflammation sooner and...

Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...

This small case series suggests upadacitinib may induce and maintain steroid-free remission in some UC patients after tofacitinib failure, a potential option for people with refractory disease.

This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.

A new pediatric Phase 3 trial of filgotinib could broaden approved treatment choices for children and teens with moderate-to-severe ulcerative colitis, especially for those who have not responded to or cannot tolerate...

A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...

Researchers are testing whether short-term dual therapy with vedolizumab plus tofacitinib can induce remission in people with moderate–severe UC who have failed prior TNF blockers. If effective and safe, this approach...

Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...

Real-world PSP registries can show how long people stay on vedolizumab and how it’s used alongside or compared with other advanced therapies like tofacitinib. That information can help patients and clinicians understand...

Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.

For people with ulcerative colitis who have already tried and failed one or more advanced therapies, this study suggests upadacitinib may lead to higher rates of steroid-free clinical remission and endoscopic healing...

People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...

Upadacitinib is already used for some patients with UC and Crohn's; this article offers a structured way to think about why it can act quickly in refractory cases and what evidence would be needed to move from short‑term...

FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib...

This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.

A Phase 3 study is testing whether oral tofacitinib can induce and maintain remission in children with moderate-to-severe ulcerative colitis — a key step before pediatric regulatory approvals and wider clinical use.

Mesalamine can rarely cause myocarditis, creating a challenge for ongoing UC treatment. This report shows upadacitinib was used successfully as an alternative when biologics were considered higher cardiac risk and...

Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...

A large network meta-analysis found adalimumab reduces risk of clinical relapse in Crohn’s disease and upadacitinib reduces loss of clinical response; these findings summarize comparative maintenance therapy evidence...

Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.

Patients and clinicians managing ulcerative colitis in India may have greater access to an effective oral treatment (tofacitinib) that can reduce steroid dependence and is available as lower-cost generics. This could...

If biologic availability, infusion capacity, or therapeutic drug monitoring are limited where you live, oral JAK inhibitors could offer a practical, effective alternative for moderate‑to‑severe IBD, according to this...

A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...

This DailyMed/FDA label update affects adults with moderately to severely active ulcerative colitis because it states approved use of tofacitinib extended‑release and highlights important safety warnings and recommended...

An FDA DailyMed label update directly affects prescribing information and safety warnings for tofacitinib, a drug used in ulcerative colitis and other immune-mediated diseases. Patients and clinicians should be aware of...